Relationship between structure and intestinal absorption of bile acids with a steroid or side-chain modification.
A structure-activity relationship for bile acid (BA) intestinal absorption is known to exist. To better understand the BA structural requirements for optimal BA intestinal absorption, rabbit ileal perfusion studies were performed. Unconjugated BA: Ursodeoxycholic (UDCA) and ursocholic acid (UCA) with methyl (6MUDCA and 6MUCA) or fluoro group (6FUDCA and 6FUCA) in the 6 position and UCA with a methyl group in 23 position (23MUCA) were compared with unconjugated UDCA, UCA, deoxycholic (DCA), chenodeoxycholic (CDCA), hyocholic (HCA), and hyodeoxycholic (HDCA) acid. BA lipophilicity was evaluated by their octanol-water partition coefficient. Conjugated BA: Taurine-conjugated UDCA and UCA with a methyl group in the 23 position (T23MUDCA and T23MUCA) were compared with the corresponding taurine-conjugated natural analogs. An analog of glycine-conjugated UDCA with the C24 amide bond replaced by a -CO-CH2- in the 24 position (24PUDCA) was studied and results were compared with the natural form (GUDCA). Unconjugated BA absorption was dose dependent (i.e., passive) and followed their lipophilicity: DCA > 6MUDCA > CDCA > HDCA > UDCA > HCA > 6FUDCA > 6MUCA > 6FUCA > UCA. Conjugated BA absorption was active, and Vmax was in the following order: TCA > TUDCA > TUCA > T23MUCA > T23MUDCA > 24PUDCA > GUDCA. 24PUDCA transport was also active and higher than GUDCA.


CONCLUSIONS
Passive transport is dependent on BA lipophilicity. Conjugated BAs are actively transported, and the presence of a 23-C methyl group does not improve transport when compared with the natural analogs. The substitution of the C24 amide bond with a -CO-CH2-still affords interaction of the BA with the intestinal transport carrier.
Aldini
R
R
Istituto di Scienze Chimiche, Università di Bologna, Italy.
Roda
A
A
Montagnani
M
M
Cerrè
C
C
Pellicciari
R
R
Roda
E
E
D000818:Animals; D001647:Bile Acids and Salts / Q000737:chemistry* / Q000378:metabolism* / Q000493:pharmacokinetics; D001692:Biological Transport; D002635:Chenodeoxycholic Acid / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics; D002793:Cholic Acids / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics; D003840:Deoxycholic Acid / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics; D007082:Ileum / Q000378:metabolism; D007408:Intestinal Absorption; D007700:Kinetics; D008745:Methylation; D010477:Perfusion; D011817:Rabbits; D013256:Steroids / Q000737:chemistry; D013329:Structure-Activity Relationship; D013654:Taurine / Q000737:chemistry / Q000378:metabolism; D014580:Ursodeoxycholic Acid / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics
D001647:Bile Acids and Salts; D002793:Cholic Acids; D013256:Steroids; D003840:Deoxycholic Acid; D002635:Chenodeoxycholic Acid; D013654:Taurine; D014580:Ursodeoxycholic Acid; C030712:ursocholic acid